What Does Fluoxetine Deplete? 3 Nutrients Affected

Fluoxetine is a selective serotonin reuptake inhibitor prescribed to approximately 25 million Americans annually under brand names Prozac and Sarafem for major depressive disorder, obsessive-compulsive disorder, panic disorder, bulimia nervosa, and premenstrual dysphoric disorder. According to ChEMBL mechanism-of-action data, fluoxetine inhibits the sodium-dependent serotonin transporter (SLC6A4). What distinguishes fluoxetine from other SSRIs is its exceptionally long elimination half-life of 4-6 days (including its active metabolite norfluoxetine), compared to escitalopram's 29.5 hours or sertraline's 26 hours. This ultra-long half-life means fluoxetine effectively self-tapers, producing far less discontinuation syndrome than other SSRIs, but also means serotonin pathway disruption and nutrient depletion effects persist for days to weeks after the drug is stopped.

The Comparative Toxicogenomics Database catalogs 211 gene interactions for fluoxetine, with 4,999 total disease associations — one of the largest molecular footprints among SSRIs, reflecting extensive research spanning three decades since Prozac's landmark approval in 1987. The three nutrient depletions flow from serotonin reuptake inhibition affecting three downstream pathways. Sodium depletion occurs through SIADH when serotonergic stimulation triggers inappropriate ADH release. Folate demand increases because accelerated serotonin turnover requires more BH4 cofactor synthesis. Melatonin production decreases because altered pineal serotonin dynamics change the substrate availability for N-acetyltransferase. The folate connection is particularly important because treatment-resistant depression — affecting roughly 30% of patients — is independently associated with low folate status.

Across 429 randomized controlled trials involving 238,071 patients in fluoxetine research indexed by CTD, the evidence base is the most extensive of any antidepressant in history. Across 212 million rows in Kelda's database, fluoxetine's depletion pattern matches other SSRIs in nutrient identity but differs in temporal profile. The 4-6 day half-life means steady-state melatonin suppression is more complete (no interdose recovery windows), SIADH risk persists longer after dose changes, and folate demand remains elevated for weeks after discontinuation. The clinical advantage of this long half-life — essentially zero withdrawal symptoms — comes with the trade-off of more persistent nutrient pathway disruption.